Previous analyses of the association between peripheral arterial disease and other vascular events have largely focused on peripheral arterial disease and ischaemic heart disease or stroke.
Patients were followed for 1 year after treatment with repeated laboratory screens, measures of clinical disease activity, and analyses of the subsets of peripheral blood lymphocytes.
We additionally included several other parasitic protists (Entamoeba histolytica, Trichomonas vaginalis, Trypansoma brucei, and Plasmodium falciparum) in our analyses of the core and peripheral exosome components for comparison, building on the work of previous researchers in this field [ 1, 23, 24, 26- 33].
For discriminatory analyses of the individual assessment of peripheral perfusion, we used predefined cutoff values for abnormal peripheral perfusion on each independent parameter.
A detailed clinical history and the subsequent quantitative and functional analyses of the lymphocyte subpopulations in the peripheral blood is crucial to classify as complete (<1%) or partial (95 99%) the disease and to guide clinicians in terms of patient isolation, vaccination, prophylaxis for opportunistic infections, use of irradiated blood products and immunological reconstitution.
The diagnosis of CLL was based on the original analyses of the bone marrow and the peripheral blood samples, and we accepted the diagnosis of CLL as recorded in the patients' hospital files.
The percentage of IL-17 producing T-cells was analysed in the peripheral blood of 30 SLE patients and 16 healthy controls.
As a proof of concept, we analysed the peripheral blood of a CD patient who had undergone long-term treatment with infliximab (9 years).
In the present study, we used an improved version of this system to analyse the peripheral blood of 28 patients with colorectal carcinoma, five patients with non-cancerous intestinal diseases and six normal controls for the presence or absence of CK20 mRNA and to investigate the relationship between the mRNA results and prognosis.
Consequently, other creative strategies are being developed to monitor surrogate markers of antiangiogenic activity, for example, ex vivo analyses of isolated peripheral blood cells.
